Fig. 3: In vitro and In vivo PK SARS-CoV-2 PLpro inhibitors.
From: Design of quinoline SARS-CoV-2 papain-like protease inhibitors as oral antiviral drug candidates
a Plasma drug concentration of Jun13306, Jun13307, Jun13308, and Jun13317 in C57BL/6J mice (6 to 8 weeks old) following p.o. administration of 50 mg/kg of compounds in 0.5% methylcellulose and 2% Tween 80 in water (n = 3 per group). b Plasma drug concentrations of Jun13338, Jun1393, Jun13126, and Jun13296 in C57BL/6J mice (6 to 8 weeks old) following p.o. administration of 50 mg/kg of compounds in 0.5% methylcellulose and 2% Tween 80 in water (n = 3 per group). c Plasma drug concentrations of Jun13296 in C57BL/6J mice (6 to 8 weeks old) following p.o. administration of 50 mg/kg and i.v. injection of 10 mg/kg (n = 3 per group) of compound. The error bars are mean ± s.d. d In vivo pharmacokinetic parameters of Jun13296 in C57BL/6J mice. e In vitro pharmacokinetic parameters of Jun13296. T1/2, half-life; Tmax, time for maximal concentration; Cmax, maximum plasma concentration; AUC0-t, area under the curve from time zero to time t; AUCt-∞, area under the curve from time t to infinity; CL, clearance; MRT, mean residence time; Vss, volume of distribution; F, oral bioavailability. Source data are provided as a source data file.
